Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback